证券代码：000739 证券简称：普洛药业 公告编号：2025-67 普洛药业股份有限公司 （4）回购期限：自公司董事会审议通过本次回购股份方案之日起 12 个月内。 （5）回购资金来源：自有资金及金融机构回购贷款。（截至本公告披露日， 中国农业银行股份有限公司东阳市支行已向公司出具了《中国农业银行贷款承诺 函》，同意向公司提供不超过 32,400 万元人民币的股票回购贷款。） 公司实际贷款金额不超过本次回购方案金额的上限，且具体业务满足《中国 人民银行、金融监管总局、中国证监会关于设立股票回购增持再贷款有关事宜的 通知》等要求，并符合银行按照相关规定制定的贷款政策、标准和程序。 2.截至本公告披露日，公司持股 5%以上股东无减持计划。 关于 2025 年第二次回购公司股份方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1. 普洛药业股份有限公司（以下简称"公司"）拟使用自有资金及金融机 构回购贷款通过深圳证券交易所交易系统以集中竞价交易方式回购公司股份，主 要内容如下： （1）回购股份的用途：本次回购股份拟用于股权激励或员工持股计 ...

普洛药业（000739）(000739.SZ)披露025年第二次回购公司股份方案，公司回购股份拟用于股权激励或 员工持股计划，本次回购资金总额不低于人民币1.8亿元(含)且不超过人民币3.6亿元(含)。本次回购股份 价格不超过人民币23元/股(含)。回购期限自公司董事会审议通过本次回购股份方案之日起12个月内。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-66 普洛药业股份有限公司 第九届董事会第十七次会议决议公告 2025 年 11 月 20 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）第九届董事会第十七次会议通 知于2025年11月8日以短信及电子邮件等方式发出。会议于2025年11月18日在公 司一楼会议室以现场会议的方式召开，本次会议由董事长祝方猛先生主持。会议 应出席董事9名，实际出席董事9名，公司部分高管列席了本次会议。本次会议的 召开符合《公司法》和《公司章程》的有关规定。经与会董事审议表决，通过如 下决议： 一、《关于 2025 年第二次回购公司股份方案的议案》 公司拟使用自有资金及金融机构回购贷款通过深圳证券交易所交易系统以 集中竞价交易方式回购公司股份，本次回购股份拟用于股权激励或员工持股计划。 本次回购股份价格不超过人民币 23 元/股，回购资金总额：不低于人民币 18,000 万元（含）且不超过人民币 36,000 万元（含）。在回购价格不超过人民币 23 元/股的条件下，按回 ...

每经AI快讯，11月19日，普洛药业(000739.SZ)公告称，公司拟使用自有资金及金融机构回购贷款通过 深圳证券交易所交易系统以集中竞价交易方式回购公司股份，回购股份价格不超过人民币23元/股，回 购资金总额为不低于人民币1.8亿元（含）且不超过人民币3.6亿元（含）。预计可回购股份数量为783万 股—1,565万股，约占公司总股本的0.68%—1.35%。回购期限为自董事会审议通过回购股份方案之日起 12个月内。若公司在股份回购完成后36个月内未能实施前述用途，未使用部分将依法履行相关程序后予 以注销。 ...

普洛药业公告称，公司拟以集中竞价方式回购股份，用于股权激励或员工持股计划，若36个月内未实 施，未使用部分将注销。回购资金总额1.8亿至3.6亿元，回购价不超23元/股，预计回购783万至1565万 股，占总股本0.68%-1.35%，回购期限为董事会通过方案之日起12个月，资金源于自有资金及金融机构 贷款。截至公告披露日，持股5%以上股东无减持计划。本次回购存在价格、方案实施等风险。 ...

Core Viewpoint - The company is facing pressure in its raw material and formulation businesses, while the CDMO (Contract Development and Manufacturing Organization) business is developing positively, indicating potential for improvement in profitability [1]. Financial Performance - For Q1-Q3 2025, revenue reached 7.764 billion yuan, a year-on-year decrease of 16.43%, with net profit attributable to shareholders at 700 million yuan, down 19.48% [2]. - In Q3 alone, revenue was 2.319 billion yuan, a decline of 18.94%, and net profit attributable to shareholders was 137 million yuan, down 43.97% [2]. - The gross profit margin remained stable at 25.02% for Q1-Q3 2025, an increase of 0.79 percentage points year-on-year, while the net profit margin was 9.02%, a decrease of 0.34 percentage points [2]. - In Q3, the gross profit margin was 23.36%, up 0.18 percentage points year-on-year, but the expense ratio increased, leading to a net profit margin of 5.91%, down 2.64 percentage points year-on-year [2]. CDMO Business Development - The raw material intermediate business is under pressure due to external macroeconomic conditions and weak demand in the industry cycle [3]. - The formulation business is accelerating its multi-variety strategy, with over 120 formulation varieties and 68 projects under research as of H1 2025 [3]. - The CDMO business is thriving, with 1,180 ongoing projects, a year-on-year increase of 35%, including 377 commercial projects (up 19%) and 803 projects in the research phase (up 44%) [3]. - A total of 134 API (Active Pharmaceutical Ingredient) projects are in progress, with 30% growth year-on-year, and 24 have entered the commercialization stage [3]. - The company has signed confidentiality agreements with over 650 domestic and international innovative drug companies [3]. Catalysts - The acceleration of drug approval progress and unexpected demand at the product terminal are seen as positive catalysts for the company [4].

格隆汇11月14日丨普洛药业(000739.SZ)公布，控股子公司浙江普洛康裕制药有限公司收到国家药品监 督管理局签发的注射用盐酸地尔硫䓬《药品注册证书》。注射用盐酸地尔硫䓬用于以下治疗：（1）阵 发性室上性心动过速、心房颤动或心房扑动。用于阵发性室上性心动过速快速转化为窦性节律；用于暂 时性控制心房颤动或心房扑动过程中过快的心室率；（2）手术时异常高血压的急救处置；（3）高血压 急症；（4）不稳定心绞痛。 ...

每经AI快讯，11月14日，普洛药业（000739）(000739.SZ)公告称，公司控股子公司浙江普洛康裕制药 有限公司收到国家药品监督管理局签发的注射用盐酸地尔硫《药品注册证书》。该药品用于阵发性室上 性心动过速、心房颤动或心房扑动的治疗，2024年度中国院内市场规模为400万支，销售金额为1.4亿 元。注射用盐酸地尔硫获得药品注册证书，视同通过仿制药质量和疗效一致性评价，将具备后续参加国 家药品集中采购的资格，有利于扩大该产品的市场销售，提高市场竞争力。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-65 普洛药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）控股子公司浙江普洛康 裕制药有限公司收到国家药品监督管理局（以下简称"药监局"）签发的注射用 盐酸地尔硫䓬《药品注册证书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：注射用盐酸地尔硫䓬 2、剂型：注射剂 3、规格：10mg 4、注册分类：化学药品 4 类 5、上市许可持有人：浙江普洛康裕制药有限公司 6、生产企业：浙江普洛康裕制药有限公司 7、证书编号：2025S03342 8、药品批准文号：国药准字 H20255882 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 注射用盐酸地尔硫䓬用于以下治疗：（1）阵发性室上性心动过速、心房颤 动或心房扑动。用于阵发性室上性心动过速快速转化为窦性节律；用于暂时性控 制心房颤动或心房扑动过程中过 ...

Core Viewpoint - The article discusses the significant price reductions for Novo Nordisk's drugs under the Trump administration's "Most Favored Nation Pricing" policy, which is expected to reshape the pharmaceutical landscape in both the U.S. and China, creating new opportunities and challenges for various companies in the industry [6][8]. Policy Background - The "Most Favored Nation Pricing" policy aims to address the high drug prices in the U.S. by requiring that drug prices be aligned with the lowest prices in OECD countries, with penalties for non-compliance [8][9]. - The policy has evolved from previous attempts and is now being implemented through a combination of voluntary negotiations and Medicare coverage exchanges, reducing legal risks for the government [9]. Opportunities for Chinese Companies - Three categories of Chinese companies are identified as potential beneficiaries of the new pricing policy: 1. **Leading CDMO Companies**: Companies like WuXi AppTec are positioned to benefit from cost-cutting collaborations with multinational pharmaceutical firms, as they can provide both technical and cost advantages [14][15]. 2. **Innovative Drug BD Leaders**: Chinese companies are increasingly involved in business development transactions with multinational firms, leading to a surge in the licensing market for innovative drugs [16]. 3. **Specialty API Manufacturers**: The growth of GLP-1 drugs is expected to create significant demand for high-purity intermediates, with Chinese firms holding a substantial share of global production capacity [17]. Risk Management Strategies - Companies facing pressure from the new pricing policy are advised to adopt specific strategies: 1. **Innovative Drug Companies**: Firms like BeiGene are diversifying their markets to mitigate pricing risks, focusing on expanding into Europe and Southeast Asia [20]. 2. **Small CDMO Firms**: These companies should enhance their capabilities in niche markets or expand regionally to differentiate themselves from larger competitors [22]. Investment Logic - The article outlines three main investment lines in the Chinese pharmaceutical sector: 1. **Core Line**: Focus on leading CDMO firms and innovative drug BD leaders that have secured significant contracts and collaborations [29][30]. 2. **Elastic Line**: Specialty API manufacturers that are experiencing growth due to increased demand for GLP-1 drugs [31]. 3. **Optimization Line**: Companies that are expanding their international presence and improving their operational capabilities to adapt to the changing market landscape [31].